Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 17/20 | 0.67 |
| ▸ | BACE1 | P56817 | 16/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167952 | 1.00 | CTSD (0.67) | CTSDBACE1CYP3A4 | |
| SCHEMBL5713938 | 1.00 | CTSD (0.67) | CTSDBACE1CYP3A4 | |
| SCHEMBL13315982 | 0.93 | BACE1 (0.68) | CTSDBACE1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3172343 | 0.92 | BACE1 (0.67) | CTSDBACE1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3172335 | 0.92 | BACE1 (0.67) | CTSDBACE1CYP3A4 | |
| SCHEMBL3162119 | 0.83 | CTSD (0.70) | CTSDBACE1CYP3A4 | |
| SCHEMBL3174867 | 0.83 | BACE1 (0.83) | CTSDBACE1CYP3A4 | |
| SCHEMBL3162112 | 0.83 | CTSD (0.70) | CTSDBACE1CYP3A4 | |
| SCHEMBL5510425 | 0.83 | BACE1 (0.83) | CTSDBACE1CYP3A4 | |
| SCHEMBL5229148 | 0.83 | BACE1 (0.54) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | claimed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | claimed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | claimed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | CTSD 185/4885BACE1 1/4885CYP3A4 2552/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | CTSD 107/4885BACE1 1/4885CYP3A4 3553/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | CTSD 185/4885BACE1 1/4885CYP3A4 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.